Post-market Reviews of Pulmonary Arterial Hypertension medicines and biological Disease Modifying Anti Rheumatic Drugs to treat severe chronic plaque psoriasis
Page last updated: 2 May 2016
The public consultation process is now open for the following two post-market reviews:
- Pulmonary Arterial Hypertension (PAH) medicines; and
- biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) to treat severe chronic plaque psoriasis.
Interested organisations and individuals are invited to provide a submission addressing the reviews’ Draft Terms of Reference.
To make a submission to either of these reviews, please go to the relevant web page:
- for PAH Medicines; or
- for bDMARDs.
Submissions will be accepted from 2 May 2016 until 5pm on 16 May 2016, in line with the Post-market Review Framework.
